Albumin versus various colloids including several HES preparations has been evaluated in many recent trials in cardiopulmonary bypass. This trial, reporting no difference between albumin and HES 130/0.4 on coagulation variables, blood loss and immunological activity does not add any new information to the body of evidence already present in the area.
– Kathrine Holte
NATA: Network for the advancement of Patient Blood Manegement, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and ther heathcare professionals.
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.